natgillin/translations-raw huggingface dataset:
9.0 mm, round, normal convex, white film-coated tablets debossed “OZ” over “7.5” on one side and “G” on the other side.
9,0 mm, ümarad, normaalse kumerusega, valged õhukese polümeerikattega tabletid, mille ühele küljele on pressitud tähis „OZ”, mille all „7.5” ning teisele küljele tähis „G”.
9.0% (-9.5% to 27.5%)
9,0% (-9,5…27,5%)
9.0% (1.0% fatal)
9,0 % (1,0 % fataalsed)
9.0)
N=77
9.00 (3.97, 20.41) p<0.0001
9,00 (3,97, 20,41) p < 0,0001
9.05 E+00
9,05 E+00
9.1-10.0 mmol/l (163-180 mg/dl)
9,1-10,0 mmol/l (163-180 mg/dl)
9.17 E-04
9,17 E-04
9.2 % of the patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
9,2% patsientidest kaasati uuringusse uuringu alguses määratud paikselt retsidiveerunud haiguse staadiumis.
9.2d (7.4, NR)
9,2d (7,4; NR)
9.3% on placebo).
9,3% platseeborühmas).
9.4 (7.3-13.2) (4-week schedule)
9,4 (7,3-13,2) (4-nädalane raviskeem)
9.5 m vs 6.3 m
Üldine elulemusab
9.5 mg/ 24 hours
9,5 mg/
9.5 mg/24 h
9,5 mg/24 h
9.5 mg/24 h
DLSM
9.5 mg/24 h N = 251
N = 251
9.5 mg/24 h patch should be used for as long as the patient benefits from it.
Plaastrit annusega 9,5 mg/24 h tuleb kasutada seni, kuni patsiendil on sellest kasu.
9.5 mg/24 h transdermal patch
9,5 mg/24 h transdermaalne plaaster
9.5 mg/24 h transdermal patch rivastigmine
9,5 mg/24 h transdermaalne plaaster Rivastigmiin
9.5 mg/24 h transdermal patch).
9,5 mg/24 h transdermaalne plaaster).
9.5 mg/24 h transdermal patch).
9,5 mg/24 h transdermaalsed plaastrid).
9.5 mg/24 h.
9,5 mg/24 h.
9.57 [3.39, 15.75]; P = 0.0026 c
9,57 [3,39; 15,75]; P = 0,0026 c
9.7 (8.3, NE)
9,7 (8,3, NE)
9.70 E-02
9,70 E-02
9.8 BbCC
9,8 BbCC
9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults.
9,9...13 g/m2 ööpäevas lastel kaaluga üle 20 kg, noorukitel ja täiskasvanutel.
9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults.
9,9...13 g/m2/ööp lastel kaaluga üle 20 kg, noorukitel ja täiskasvanutel.
9.9 months (95 % C.I.: 7, 12.6) versus 6.3 months (95 % C.I.: 4.9, 9.5) for the cisplatin arm with a hazard ratio of 0.75 (0.49, 1.16).
12,6) ja tsisplatiini grupis 6,3 kuud (95 % usaldusvahemik: 4,9, 9,5); riskimäär 0,75 (0,49,
9.9 months (95 % C.I.: 7, 12.6) versus 6.3 months (95 % C.I.: 4.9, 9.5) for the cisplatin arm with a hazard ratio of 0.75 (0.49, 1.16).
elulemuse mediaan topotekaani pluss tsisplatiini grupis 9,9 kuud (95% usaldusvahemik: 7, 12,6) ja tsisplatiini grupis 6,3 kuud (95% usaldusvahemik: 4,9, 9,5); riskimäär 0,75 (0,49, 1,16).
9.9 months) or progression free survival (5.1 vs.
9,9 kuud) ega kasvaja progressioonita perioodi näitajates (5,1 vs.
9.98 E-01
9,98 E-01
9.99 E+00
9,99 E+00
9.99 E-01
9,99 E-01
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
7/7 mm Hg, 9/5 mm Hg ja 8/4 mm Hg ning püsti asendis täheldati vererõhu täiendavat langust keskmiselt vastavalt 6/6 mm Hg, 11/4 mm Hg ja 4/5 mm Hg.
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
7/7 mmHg, 9/5 mmHg ja 8/4 mmHg ning püsti asendis täheldati vererõhu täiendavat langust keskmiselt vastavalt 6/6 mmHg, 11/4 mmHg ja 4/5 mmHg.
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
Nendes uuringugruppides täheldati lamavas asendis vererõhu täiendavat langust keskmiselt vastavalt 7/7 mmHg, 9/5 mmHg ja 8/4 mmHg ning püsti asendis täheldati vererõhu täiendavat langust keskmiselt vastavalt 6/6 mmHg, 11/4 mmHg ja 4/5 mmHg.
90
50a
90 (3 bottles of 30) film-coated tablets
90 (3 pudelit, igas 30 tabletti) õhukese polümeerikattega tabletti
90 (3 bottles of 30) film-coated tablets
90 (3 pudelit, igas 30) õhukese polümeerikattega tabletti
90 (3 bottles of 30) film-coated tablets
90 õhukese polümeerikattega tabletti (3 pudelit 30 tabletiga)
90 (3 x 30 x 1) capsules (unit dose) (multipack) +
90 (3 x 30 x 1) kapslit (üksikannus) (multipakend) +
90 (3 x 30 x 1) tablets (unit dose) (bundle multipack)
90 (3 x 30 x 1) tabletti (Üksikannus) (hulgipakend, kimp)
90 (3 x 30 x 1) tablets (unit dose) (carton multipack)
90 (3 x 30 x 1) tabletti (üksikannus) (hulgipakend, karp)
90 (3 x 30) ampoules (multipack)
90 (3 x 30) ampulli (mitmikpaken d)
90 (3 x 30) sachets (multipack)
90 (3 x 30) kotikest (multipake nd)
90 (3 x 30) sachets (multipack)
90 (3 x 30) kotikest (multipakend)
90 (3x30) ampoules
90 (3 x 30) ampulli,
90 (3x30) tablets
90 (3 × 30) tabletti
90 (3x30) tablets
90 (3x30) tabletti
90 (3x30) tablets
90 tabletti
90 (3x30) tablets (multipack)
90 (3x30) tabletti (multipakend)
90 (3x30x1) capsules (unit
90 (3x30x1) kapslit
90 ampoules
90 ampulli
90 ampoules
90 ampulli,
90 AMPOULES WITH 2 ML
90 AMPULLI x 2 ml
90 capsules
90 kapslit
90 capsules
90 kõvakapslit
90 film-coated tablets
90 tabletti
90 film-coated tablets
90 õhukese polümeerikattega tabletti.
90 film-coated tablets
90 õhukese polümeerikilega
90 film-coated tablets.
90 õhukese polümeerkattega tabletti.
90 Imatinib 400 mg once daily (n = 283)
90 Imatiniib 400 mg üks kord ööpäevas (n = 283)
90 mcg/0.5 ml
90 g /0,5 ml
90 mg
(PVC/PVDC/alu)
90 mg
kalenderblister
90 mg
Spinosaad 90 mg
90 mg tablet: blue, pentagonal (major axis 9.7 mm, minor axis 9.5 mm), shallow-convex, debossed with “OTSUKA” and “90” on one side
30 mg tablett: sinine, ümar (diameeter: 8 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja
90 mg twice daily
90 mg kaks korda ööpäevas
90 mg)
28 x 90 mg)
90 ml (p<0.001)
90 ml (p<0,001)
90 ml or 100 ml*
90 ml või 100 ml
90 ml oral solution
90 ml suukaudset lahust
90 pouches
90 kotikest
90 single-dose
90 üheannuselist
90 single-dose containers
90 üheannuselist konteinerit
90 soft capsules
90 pehmekapslit
90 tablets
60 tabletti
90 tablets
90 tablett
90 tablets
90 tabletti.
90 tablets
98 tabletti
90 tablets
EU/1/08/465/020
90 tablets (multipack)
90 tabletti (multipakend)
90 tablets (PVC/PCTFE blisters)
90 tabletti (PVC/PCTFE blistrid)
90 tablets: EU/1/08/469/004
90 tabletti: EU/1/08/469/004
90 tablets: EU/1/08/469/009
90 tabletti: EU/1/08/469/009
90 tablets: EU/1/08/469/014
90 tabletti: EU/1/08/469/014
90 tablets: EU/1/08/469/019
90 tabletti: EU/1/08/469/019
90 tablets: EU/1/08/469/024
90 tabletti: EU/1/08/469/024
90 tablets: EU/1/08/480/020
90 tabletti: EU/1/08/480/020
90 tablets: EU/1/08/480/024
90 tabletti: EU/1/08/480/024
90 tablets: EU/1/10/632/006
90 tabletti: EU/1/10/632/006
90 tablets: EU/1/10/632/013
90 tabletti: EU/1/10/632/013
90 tablets: EU/1/10/632/020
90 tabletti: EU/1/10/632/020
90 tablets: EU/1/11/721/006
90 tabletti: EU/1/11/721/006
90 tablets: EU/1/11/721/013
90 tabletti: EU/1/11/721/013
90 tablets: EU/1/11/721/020
90 tabletti: EU/1/11/721/020
90 tablets: EU/1/11/723/006
90 tabletti: EU/1/11/723/006
90 tablets: EU/1/11/723/013
90 tabletti: EU/1/11/723/013
90 tablets: EU/1/11/723/020
90 tabletti: EU/1/11/723/020
90 tablets: five transparent blisters of 18 tablets each.
90 tabletti: viis läbipaistvat blistrit, igaühes 18 tabletti.
90 transdermal patches
90 transdermaalset plaastrit
90 x 1 blisters (3 pouches)
90 x 1 blistrit
90 x 1 blisters (3 pouches) +
90 x 1 blistrit
90 x 1 capsules
90 x 1 kapslit
90 x 1 film-coated tablet Bottle pack: 30 film-coated tablets
90 x 1 õhukese polümeerikattega tabletti Pudelid: 30 õhukese polümeerikattega tabletti
90 x 1 film-coated tablets
90 x 1 õhukese polümeerikattega tabletti
90 x 1 tablet (unit
90 x 1 tabletti
90 x 1 tablet (unit dose)
90 x 1 tablett
90 x 1 tablet (unit dose)
90 x 1 tabletti
90 x 1 tablet (unit dose)
90 x 1 tabletti (üksikannus)
90 x 1 tablets
90 x 1 tabletti
90 x 1 tablets
90 x 1tabletti
90 x 1 tablets
90x1 tabletti
90 x 1 tablets (unit dose)
90 x 1 tablett (üksikannus)
90 x 1 tablets (unit dose)
90 x 1 tabletti
90 x 1 tablets (unit dose)
90 x 1 tabletti (üheannuseline blister)
90 x 1 tablets (unit dose)
90 x 1 tabletti (üheannuseline)
90 x 1 tablets (unit dose)
90 × 1 tabletti (üksikannus)
90 g PRE-FILLED SYRINGE
90 g SÜSTEL
90% of patients on Tarceva developed rash within the first 44 days.
90% Tarceva’ga ravitud patsientidest tekkis lööve esimese 44 päeva jooksul.
90% of patients treated with Imlygic experienced influenza-like symptoms.
90% Imlygic’uga ravitud patsientidest ilmnesid gripilaadsed sümptomid.
90% of patients were CTCAE grade 0 at baseline, and 10% were CTCAE grade 1 at baseline.
90%-l patsientidest esines ravi alguses CTCAE aste 0 ja 10%-l aste 1.
90-93 kg
90–93 kg
90.5 days
90,5 päeva
90.52 (83.8 to 9)
90,52 (83,8–98,4)
90.8 (11.70)
R092670-PSY-3003
900 1 days)
900 1
900 1 days)
RADIGM
900 1080 1260
Time since randomisation (days)
900 ays)
900 (päevad
900 mg at week 3; then 900 mg every 2 weeks
900 mg 3. nädalal; seejärel 900 mg iga 2 nädala järel
900 mg tablets: - Carton box with 5, 25 or 50 tablets in PVC/aluminium heat sealed blisters.
900 mg tabletid: - kartongkarp 5, 25 või 50 tabletti PVC/alumiinium kuumsuletud blisteris
9000 microgram (mcg/ml) for patients under 2 years of age
9000 mikrogrammi (μg/ml) alla 2-aastastel patsientidel
90429 Germany
90429 Nürnberg Saksamaa
90650 Oulu Finland
90650 Oulu Soome
90x1 film-coated tablets
100x1 õhukese polümeerikattega tabletti
90x1 film-coated tablets
90x1 õhukese polümeerikattega tabletti
90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets
90x1 õhukese polümeerikattega tabletti 100 õhukese polümeerikattega tabletti 100x1 õhukese polümeerikattega tabletti
90x1 tablets (unit dose)
90x1 tabletti (ühekordne annus)
90° angle
90° nurk
91 p = 0.029
91 p = 0,029
91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).
91% ja 93% patsientidest esialgse raviga vastavalt febuksostaat 80 mg ja 120 mg-ga, sUA <6 mg/dl, 36.- ndal kuul).
91.1%, p=0.002*) and more discontinuations from the treatment due to adverse events (26.7% vs.
91,1%; p = 0,002*) ja kõrvaltoimetest tingitud ravi katkestamisi (26,7% vs.
91.9, 100.0
ägenemine (relapser)
91070 Bondoufle France
91070 Bondoufle Prantsusmaa
911) total antigenic mass units
911) antigeeni kogumassi ühikut
91192 GIF-SUR-YVETTE Cedex
91192 GIF-SUR-YVETTE
92
CI)
92 micrograms
92 mikrogrammi
92 micrograms /
92 mikrogrammi /
92 patients treated with docetaxel in combination with trastuzumab.
92 patsiendi kombinatsioonravil dotsetakseeli ja trastusumaabiga;
92 patients treated with docetaxel in combination with trastuzumab.
92 patsiendi kombinatsioonravil dotsetakseeli ja trastutsumabiga.
92 patients treated with docetaxel in combination with trastuzumab.
92 patsiendi kombinatsioonravil dotsetakseeli ja trastuzumabiga.
92 patients treated with docetaxel in combination with trastuzumab.
92 patsiendil, keda raviti dotsetakseeli ja trastuzumabi kombinatsiooniga.
92 subjects in the vaccine group had immunogenicity data at the [M107- M113] interval after the first vaccine dose with a median follow-up of 8.9 years.
92 isikul vaktsineeritute grupist olid immunogeensusandmed vahemikus [M107...M113] peale esimest vaktsiiniannust keskmiselt 8,9aastase jälgimisperioodi jooksul.
92.2 (11.72)
R092670-SCH-201
92.8% to 98.6%
92,8...98,6
92.9% to 98.0%
92,9...98,0
92284 Suresnes cedex - France
92284 Suresnes cedex Prantsusmaa
92289 Ursensollen Germany
92289 Ursensollen Saksamaa
92800 - Puteaux France
92800 – Puteaux Prantsusmaa
93%), when given 6 months after MabThera as compared to patients only receiving methotrexate.
93 %) suhtes, kui neid manustati 6 kuud pärast MabThera’t, võrreldes ainult metotreksaati saavate patsientidega.
93.2 % of patients received ASA concomitantly plus thienopyridine treatment and 6.8 % ASA only.
93,2% patsientidest said samaaegselt ravi ASA ja tienopüridiini derivaadiga; 6,8% ainult ASA-ga.
93.4, 97.9
D168V
93.9 (89.1 to 102.1)
93,9 (89,1–102,1)
939 patients treated with pemetrexed plus cisplatin induction, 539 patients were randomised to maintenance treatment with pemetrexed or placebo.
Pemetrekseed + tsisplatiin induktsioonravi saanud 939 patsiendist randomiseeriti 539 patsienti saama säilitusravi pemetrekseedi või platseeboga.
939 patients treated with pemetrexed plus cisplatin induction, 539 patients were randomised to maintenance treatment with pemetrexed or placebo.
Pemetrekseedi + tsisplatiini induktsioonravi saanud 939 patsiendist randomiseeriti 539 patsienti saama säilitusravi pemetrekseedi või platseeboga.
94 (37%)a
94 (37%) a
94 (37.8%)a
94 (37,8%)a
94 (83.9%) patients randomised to the BAT arm crossed over to ruxolitinib treatment at Week 32 or after, limiting the comparison between the two arms after Week 32.
94 (83,9%) BAT’i rühma randomiseeritud patsientidest läks 32. nädalal või hiljem üle ruksolitiniibravile, mis seab piirangud kahe rühma võrdlemisse pärast 32. nädalat.
94.3% to 98.9%
94,3...98,9
94.42% B)
94,42%B)
94.7, 98.1
42,9 (3)d
94.8 vs.
94,8 vs.
94.9 (77.7 to 117.0)
94,9 (77,7…117,0)
94/129 (72.9)
Üldsuremus 40/129 (31,0)
9400 Nørresundby
Sogeval ApS
9400 Nørresundby
Strømmen 69400 Nørresundby
941.4 mg liquid paraffin
941,4 mg vedelat parafiini
94250 Gentilly France
94250 Gentilly Prantsusmaa
95 % C.I.
95% CI
95 % CI
95% usaldusvahemik
95 % CI for HR
HR 95% CI
95 % CI for median
95 % CI mediaan
95 % CI for median
95% CI mediaan
95 % CI for median
keskmine (k.) keskmise 95 % CI
95 % of dogs had returned to normal plasma testosterone levels within 2.5 years of implantation.
95%-l koertest taastus vereplasma normaalne testosteroonitase 2,5 aasta jooksul pärast implantatsiooni.
95 % two-sided CI on the treatment difference (Eurartesim - Comparator); p-value
Ravi vahe (Eurartesim – võrdlusravim) 95% kahepoolne usaldusvahemik; p- väärtus
95 (35.4 %) p<0.028. No signs of any increase adverse effects were noted in this study.
Selles uuringus ei märgatud kõrvaltoimete esinemissageduse suurenemist.
95 (37 %) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (“pretreated patients”) whereas 165 (63 %) had not (“untreated patients”).
95 patsienti (37 %) olid eelnevalt saanud kemoteraapiat kas aktseleratsioonifaasi või blastse kriisi raviks („eelnevalt ravitud patsiendid”) ja 165 (63 %) ei olnud ravi saanud („ravimata patsiendid”).
95 mg/23.75 mg modified-release hard capsule
95 mg/23,75 mg toimeainet modifitseeritult vabastav kõvakapsel
95 mg/23.75 mg modified-release hard capsules
95 mg/23,75 mg toimeainet modifitseeritult vabastav kõvakapsel
95 mg/23.75 mg, 145 mg/36.25 mg, 195 mg/48.75 mg and 245 mg/61.25 mg.
145 mg/36,25 mg, 195 mg/48,75 mg ja 245 mg/61,25 mg.
95 ml oral solution (1 bottle) Oral syringe
95 ml suukaudne lahus (1 pudel) Suusüstal
95% CI
0,0107
95% CI
0,5853
95% CI
17,4
95% CI
95% usalduspiir
95% CI
95% usalduspiirid
95% CI
HR (95
95% CI
p-väärtus
95% CI (0.56; 0.76)
95% CI (0,56; 0,76)
95% CI (0.69; 0.93)
95% CI (0,69; 0,93)
95% CI (0.75, 1.03) p-value 0.1135
95% CI (0,75; 1,03) p-väärtus 0,1135
95% CI = 1.08-2.26, p = 0.018).
95 % CI = 1,08...2,26; p = 0,018).
95% CI = 1.08-2.26, p = 0.018).
HR = 1,56; 95 % CI = 1,08...2,26; p = 0,018).
95% CI for Difference in Response Rates4
Ravivastuse määrade erinevuse 95% CI4
95% CI for Hazard ratio
Riski suhtarvu 95% CI
95% CI for hazard ratio (0.4316 to 0.6430) p-valuea <0.0001
95% CI riskisuhte jaoks (0,4316…0,6430) p-väärtusa <0,0001
95% CI for hazard ratio (0.6730 to 1.0013) p-value a 0.0510
95% CI riskisuhte jaoks (0,6730…1,0013) p-väärtus a 0,0510
95% CI for HR
HR 95 % CI
95% CI for HR
HR 95% CI
95% CI for HR
Riskisuhe, 95% usaldusvahemik
95% CI for median
95 % CI mediaan
95% CI for median
95% CI mediaan
95% CI for median
Mediaani 95% CI
95% CI for median (days)
Mediaanse väärtuse 95% usaldusvahemik (päevades)
95% CI for Response Rates3
Ravivastuse määrade 95% CI3
95% CI of Difference (p-value)
Erinevuse 95% CI (p-väärtus)
95% CI of ORR
ORR 95% CI
95% CI of Rate5
Määra 95% CI5
95% CI: 1.05,
95% CI: 1,05,
95% CI: 1.4, 17.9
95% CI: 1,4; 17,9
95% CI: 22.9, 39.9
95% CI: 22,9; 39,9
95% CI: 29.0, 53.7
95% CI: 29,0; 53,7
95% CI: 3.8, 24.6
95% CI: 3,8; 24,6
95% CI: 4.2-9.8 months).
4,2 - 9,8 kuud).
95% CI: 4.5, 16.4 95% CI: 8.6, 23.3
95% CI: 4,5; 16,4 95% CI: 8,6; 23,3
95% CI: 6.2, 32.0
95% CI: 6,2; 32,0
95% CI: 7.0, 19.3
95% CI: 7,0; 19,3
95% CI: 8.7, 49.1
95% CI: 8,7; 49,1
95% CI: 9.0, 38.9
95% CI: 9,0; 38,9
95% CL
95% usaldusvahemik
95% Confidence Interval could not be established (single-subject data)
95% usaldusvahemikku ei olnud võimalik leida (ühe uuringus osaleja andmed)
95% confidence interval for the for the difference in proportions
95% usaldusintervall proportsionaalsete erinevuste hindamiseks
95% confidence interval for the hazard ratio
95% usaldusintervall riskimäära hindamiseks
95% confidence intervals
95% usalduspiirid (%)
95% confidence intervals calculated as LS Mean  1.96  Standard Error.
95% usaldusvahemiku arvutamisel lähtutakse valemist: vähimruutude keskmine  1,96 x standardhälve.
95% confidence intervals.
95% usaldusintervall.
95% of the dose is excreted in the urine as drug and metabolites.
95% annusest eritub uriiniga ravimina ja metaboliitidena.
95% two-sided CI on the treatment difference (Eurartesim - Comparator); p-value
Ravi vahe (Eurartesim – võrdlusravim) 95% kahepoolne usaldusvahemik; p-väärtus
95-200 Pabianice Poland
95-200 Pabianice Poola
95.33%B)
95,33%B)
95.9 ± 19.6 (n = 13)
95,9 ± 19,6 (n = 13)
95.9% to 99.9%
95,9...99,9
950 mg/m2
750 mg/m2
96 (4 x 24 x 1)
96 (4 x 24 x 1) kapslit
96 (49.2)a
96 (49,2)a
96 (4x24x1) capsules (unit
96 (4x24x1) kapslit
96 capsules
96 kapslit
96 gastro-resistant tablets
96 gastroresistentset tabletti
96 hours after the administration of Foscan, the treatment site is to be illuminated with light at 652 nm from an approved laser source.
96 tundi pärast Foscan’i manustamist tuleb ravitavat piirkonda töödelda laservalgusega lainepikkusel 652 nm.
96 to 114
96…114
96 Weeks
andmed Parameeter
96% [76,100]
Igasuguse etioloogiaga
96%, 100% and 91% were anti-HPV6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
HPV 11, HPV 16 ja HPV 18 antikehade suhtes seropositiivsed cLIA järgi ja 98%, 96%, 100% ja 91% olid vastavalt HPV 6, HPV 11, HPV 16 ja HPV 18 antikehade suhtes seropositiivsed IgG LIA järgi.
96%; p = 0.017), but not in the triple immunosuppressant trial (94% Vs.
96%; p = 0,017), kuid mitte kolme immunosupressandiga uuringus (94% vs.
96.3 (156/162)
SVR %, (n/N)
96.4
Y56Hc
96.5% CI
96,5%CI
96.85% CI
96,85% CI
96.85% CI (0.43, 0.81) p-value 0.0002
96,85% CI (0,43, 0,81) p-väärtus 0,0002
9659
Insult
97 (49.7)a
97 (49,7)a
97.5% confidence intervals are used for the primary efficacy endpoints (overall SVR12 rate); 95% confidence intervals are used for additional efficacy endpoints (SVR12 rates in HCV genotype 1a and 1b-infected subjects).
Esmaste efektiivsuse tulemusnäitajate (SVR12) puhul kasutati 97,5% usaldusvahemikku; täiendavate efektiivsuse tulemusnäitajate (SVR12 genotüüp 1a ja 1b patsientidel) puhul kasutati 95% usaldusvahemikku.
97.8 vs.
97,8 vs.
97.8b
97,8b
97.9 vs.
97,9 vs.
97/100 ut SVR1
94,1, 98,4
9785-CL-0222 (TERRAIN) study (chemotherapy-naïve patients)
9785-CL-0222 (TERRAIN) uuring (kemoteraapiat mittesaanud patsiendid)
98 (2 x 49 x 1) tablets
98 (2 x 49 x 1) tabletti
98 (2 x 49 x 1) tablets (unit dose) (multipack)
98 (2 x 49 x 1) tabletti (üheannuseline) (multipakend)
98 (2 x 49) capsules
98 (2 x 49) kapslit
98 (2 x 49) tablets (multipack)
98 (2 x 49) tabletti (multipakend)
98 (25.7)a
98 (25,7)a
98 (2x49) tablets
98 (2x49) tabletti
98 (2x49) tablets (multipack)
98 (2x49) tabletti (hulgipakend)
98 (2x49) tablets (multipack)
98 (2x49) tabletti (mitmikpakend)
98 (2x49) tablets (multipack)
98 (2x49) tabletti (multipack)
98 (2x49) tablets (multipack)
98 (2x49) tabletti (multipakend)
98 (2x49x1) tablets (multipack)
98 (2x49x1) tabletti (hulgipakend)
98 (2x49x1) tablets (multipack)
98 (2x49x1) tabletti (multipack)
98 (2x49x1) tablets (multipack) (unit dose)
98 (2x49x1) tabletti (mitmikpakend) (üksikannus)
98 coated tablets
98 kaetud tabletti
98 film-coated tablets
98 õhukese polümeerikattega tabletid.
98 film-coated tablets (2x49x1)
98 õhukese polümeerikattega tabletti (2x49; perforeeritud üheannuseline blister)
98 film-coated tablets (calendar blister)
98 õhukese polümeerikattega tabletti (kalenderblister)
98 film-coated tablets in calendar blisters
polümeerikattega tabletti kalenderblistrites 98 õhukese
98 hard capsules
98 kõvakapslit
98 modified-release tablets.
98 toimeainet modifitseeritult vabastavat tabletti.
98 orodispersible tablets
98 õhukese polümeerikattega tabletti
98 tablets
(PVC/PVDC/Alu)
98 tablets
98 tabletid
98 tablets (2x49, PA/Alu/PVC blisters)
98 tabletti (2 x 49 PA/Al/PVC blistrit)
98 tablets (2x49, PA/Alu/PVC blisters)
98 tabletti (2 x 49 PA/Alu/PVC blistrit)
98 tablets (2x49x1, PVC/PCTFE single-unit-dose blisters)
98 tabletti (2 x 49 x 1, PVC/PCTFE üheannuselist blistrit)
98 tablets (multipack)
98 tabletti (multipakend)
98 tablets (PVC/PCTFE blisters)
98 tabletti (PVC/PCTFE blistrid)
98 tablets: EU/1/08/480/006
98 tabletti: EU/1/08/480/006
98 tablets: EU/1/08/480/018
98 tabletti: EU/1/08/480/018
98 tablets: EU/1/10/632/007
98 tabletti: EU/1/10/632/007
98 tablets: EU/1/10/632/014
98 tabletti: EU/1/10/632/014
98 tablets: EU/1/10/632/021
98 tabletti: EU/1/10/632/021
98 tablets: EU/1/11/721/007
98 tabletti: EU/1/11/721/007
98 tablets: EU/1/11/721/014
98 tabletti: EU/1/11/721/014
98 tablets: EU/1/11/721/021
98 tabletti: EU/1/11/721/021
98 tablets: EU/1/11/723/007
98 tabletti: EU/1/11/723/007
98 tablets: EU/1/11/723/014
98 tabletti: EU/1/11/723/014
98 tablets: EU/1/11/723/021
98 tabletti: EU/1/11/723/021
98 x 1 film-coated tablets
98 x 1 õhukese polümeerikattega tabletid.
98 x 1 film-coated tablets
98 x 1 õhukese polümeerikattega tabletti
98 x 1 film-coated tablets
98 x 1 õhukese polümeerikattega tabletti.
98 x 1 film-coated tablets
98 × 1 õhukese polümeerikattega tabletid.
98 x 1 film-coated tablets
98 × 1 õhukese polümeerikattega tabletti.
98 x 1 Film-coated tablets.
98 x 1 Õhukese polümeerikattega tabletid.
98 x 1 tablet
98 x 1 tabletid
98 x 1 tablet (unit
98 x 1 tabletti
98 x 1 tablet (unit dose)
98 x 1 tablett
98 x 1 tablet (unit dose)
98 x 1 tablett (üheannuseline)
98 x 1 tablet (unit dose)
98 x 1 tablett (ühikuannus)
98 x 1 tablet (unit dose)
98 x 1 tabletti
98 x 1 tablet (unit dose)
98 x 1 tabletti (üksikannus)
98 x 1 tablets
98 x 1 tablett
98 x 1 tablets
98 x 1 tabletti
98 x 1 tablets (multipack)
98 x 1 tabletti (multipakend)
98 x 1 tablets (unit
98 x 1 katmata
98 x 1 tablets (unit dose)
98 x 1 tabletti (üheannuseline blister)
98 x 1 tablets (unit dose)
98 x 1 tabletti (üksikannus)
98 x 1 tablets (unit dose)
98 × 1 tabletti (üksikannus)
98.0
D168Y
98.52% CI (0.57, 0.93) p-value 0.0018
98,52% CI (0,57; 0,93) p-väärtus 0,0018
98.7 vs.
98,7 vs.
980 (10 x 98) tablets
980 (10 x 98) tabletti
980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
980 Great West Road, Brentford, Middlesex TW8 9GS, Ühendkuningriik.
980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom
980 Great West Road, Brentford, Middlesex, TW8 9GS Ühendkuningriik
980 tablets (10 x 98 tablets)
980 tabletti (10 x 98 tabletti)
99 % of patients (243/246) enrolled in the STS phase III study, including the 15 subjects, received anthracycline.
STS III faasi uuringusse kaasatud patsientidest 99 % (243/246), kaasaarvatud 15 isikut, said antratsükliini.
99 tablets
99 tabletti
99 x 106 cells/l
99 x 106 rakku/l
99-300 Kutno Poland
99-300 Kutno Poola
99.4
Vähimruutu
99.79% CI (0.25, 0.73)
99,79% CI (0,25, 0,73)
99.9]
määr1
999 mg metaflumizone and 999 mg amitraz
999 mg metaflumisooni ja 999 mg amitrazi
99mTc-depreotide binds to the extent of about 12% to plasma proteins in patients and healthy volunteers.
99mTc-depreotiid seondub tervetel vabatahtlikel ja patsientidel plasma valkudega umbes 12% ulatuses.
99mTc-depreotide is not recommended for use in patients below the age of 18 as data are not available for this age group.
Alla 18 aastastel patsientidel ei ole 99mTc-depreotiidi kasutamine soovitatav, sest selle vanusegrupi kohta puuduvad andmed.
99mTc-depreotide is therefore contraindicated in pregnancy. (See section 4.3)
Seepärast on 99mTc-depreotiid rasedatel vastunäidustatud (vt lõik 4.3).